Cambridge-based cell therapy firm Vericel Corp. has forged a $142 million deal to license a gel used to help heal burns that made just over $3 million in sales last year at an Israeli company. Vericel (Nasdaq: VCEL) will pay $17.5 million upfront and up to $125 million in milestones to license and sell the burn repair product NexoBrid […]